Tango Therapeutics price target lowered to $14 from $16 at Guggenheim
PremiumThe FlyTango Therapeutics price target lowered to $14 from $16 at Guggenheim
4M ago
Tango Therapeutics price target lowered to $13 from $18 at Barclays
Premium
The Fly
Tango Therapeutics price target lowered to $13 from $18 at Barclays
4M ago
Medivir licensee Tango Therapeutics discontinues TNG348 clinical program
Premium
The Fly
Medivir licensee Tango Therapeutics discontinues TNG348 clinical program
4M ago
Tango Therapeutics price target raised to $17 from $16 at H.C. Wainwright
PremiumThe FlyTango Therapeutics price target raised to $17 from $16 at H.C. Wainwright
6M ago
Navigating the AI Minefield: Tango Therapeutics’ Struggle with Security Risks and EU Regulations
Premium
Company Announcements
Navigating the AI Minefield: Tango Therapeutics’ Struggle with Security Risks and EU Regulations
6M ago
Tango Therapeutics reports Q4 EPS (32c), consensus (28c)
Premium
The Fly
Tango Therapeutics reports Q4 EPS (32c), consensus (28c)
6M ago
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress ReleasesTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9M ago
Tango Therapeutics doses first patient in TNG348 trial
Premium
The Fly
Tango Therapeutics doses first patient in TNG348 trial
9M ago
Tango Therapeutics announces first patient dosed in Phase 1/2 trial of TNG348
Premium
The Fly
Tango Therapeutics announces first patient dosed in Phase 1/2 trial of TNG348
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100